Liquidia Corporation (LQDA) Presents at Jefferies London Healthcare Conference 2025 Transcript

Core Insights - Liquidia has successfully launched its first PRINT-enabled product, YUTREPIA, which received approval in May and generated $51.7 million in revenue during its first full quarter of launch [3]. Company Performance - The company is capturing a significant share of new patient starts and transitioning existing patients from TYVASO and TYVASO DPI to YUTREPIA, indicating strong market penetration [4]. - The sustainability of this growth is supported by the favorable product profile of YUTREPIA, which is expected to maintain its momentum in the market [4].